

Edgar Filing: TECHNE CORP /MN/ - Form 8-K

TECHNE CORP /MN/
Form 8-K
July 23, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 22, 2013

TECHNE CORPORATION
(Exact Name of Registrant as Specified in its Charter)

Minnesota	0-17272	41-1427402
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	I.R.S. Employer Identification No.)

614 Mckinley Place NE	55413
Minneapolis, MN	(Zip Code)
(Address of Principal Executive Offices)	

Registrant's telephone number, including area code: (612) 379-8854

Not Applicable
(Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- / / Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- / / Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- / / Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- / / Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On July 22, 2013, R&D Systems, Inc. ("R&D Systems"), a Minnesota corporation and wholly-owned subsidiary of Techne Corporation, acquired all of the outstanding stock of Bionostics Holdings Limited ("BHL"), a United Kingdom company from the shareholders of BHL. Through the acquisition of BHL, R&D Systems also acquired BHL's subsidiary Bionostics, Inc.,

Edgar Filing: TECHNE CORP /MN/ - Form 8-K

a Massachusetts corporation ("Bionostics").

R&D Systems acquired the shares of BHL for total consideration of approximately \$104 million in cash, of which \$13 million will be held in escrow for 18 months to secure indemnity obligations of the shareholders of BHL contained in the Share Purchase Agreement for the acquisition. The purchase price may be adjusted post-closing based on the final level of working capital of Bionostics at closing.

A copy of the press release announcing the acquisition is filed herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

99.1 Press Release, dated July 22, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TECHNE CORPORATION

Date: July 23, 2013

By: /s/ Charles R. Kummeth

Charles R. Kummeth
President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release, dated July 22, 2013.